Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares (KNSA)

Competitors to Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares (KNSA)

Aimmune Therapeutics, Inc.

Aimmune Therapeutics, Inc. specializes in developing treatments for food allergies, competing with Kiniksa Pharmaceuticals in the immunotherapy space. While Kiniksa focuses on rare diseases and inflammatory conditions, Aimmune has carved a niche in food allergy therapies, making them direct competitors in the broader therapeutic landscape where innovations in immune modulation are crucial. Aimmune’s recently commercialized therapies may provide them a competitive edge as they demonstrate proven outcomes in a well-defined market.

Amgen Inc. 

Amgen Inc. is a leading biotechnology company that develops therapies for a range of conditions including oncology, cardiovascular diseases, and inflammation. Amgen’s extensive pipeline and established market presence allow it to compete with Kiniksa Pharmaceuticals, especially in the immunology and inflammatory disease segments. Given Amgen's substantial resources, a broad portfolio of marketed products, and significant investment in R&D, they maintain a competitive advantage over Kiniksa.

Bristol Myers Squibb Company 

Bristol Myers Squibb Company competes with Kiniksa Pharmaceuticals in the field of immunology and cancer therapies. While Kiniksa targets specific rare diseases, Bristol Myers has a diverse range of treatments across multiple therapeutic areas, including autoimmune and inflammatory disorders. Bristol Myers Squibb's established reputation, significant market share, and vast resources give them a competitive edge over Kiniksa, especially in terms of market access and patient reach.

Nimbus Therapeutics

Nimbus Therapeutics is engaged in developing therapies for rare diseases and has a focus on precision medicine, which overlaps with Kiniksa's mission. Both companies are competing in similar therapeutic areas; however, Nimbus’s innovative approaches leveraging novel drug designs could pose a potential challenge to Kiniksa. While Kiniksa has progressed with its product candidates, Nimbus’s focus on leveraging computational drug design may give them a competitive edge in specific niche markets.